Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) fell 0.1% during mid-day trading on Friday . The stock traded as low as $8.47 and last traded at $8.66. 180,366 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 231,983 shares. The stock had previously closed at $8.67.
Traws Pharma Stock Performance
The firm has a market cap of $26.21 million, a price-to-earnings ratio of -0.06 and a beta of 1.46. The firm’s 50-day moving average is $5.99.
Traws Pharma Company Profile
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
Further Reading
- Five stocks we like better than Traws Pharma
- Profitably Trade Stocks at 52-Week Highs
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Expert Stock Trading Psychology Tips
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
